# Krascendo 1: HCP commentary report

> 27 verified HCP statements from 16 commentary sources · 4 findings · updated Oct 18, 2026

## Report

- Trial: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT ID: NCT06497556
- Registry: https://clinicaltrials.gov/study/NCT06497556
- Sponsor: Hoffmann-La Roche
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: sotorasib, adagrasib
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-18
- Last checked: 2026-10-18
- Release hash: 2af386ac68ea7ed0efc2c6a281e086892c6f2bb7123627e3b7921fe04daa3abb

## Counts

- HCP commentary sources screened: 26
- Sources cited by verified HCP statements: 17
- Verified HCP statements: 27
- Findings: 4
- People found in screened sources: 18
- People identity-verified: 13
- Voices cited: 15

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

KRAScendo-1 asks whether divarasib can improve outcomes over sotorasib or adagrasib for people with advanced or metastatic non-small cell lung cancer bearing KRAS G12C mutations after earlier systemic treatment. Discussion covers direct comparisons between targeted agents, progression-free and overall survival, information needed to assess benefits and risks, and potential implications for treatment choices. The sources reviewed for this edition reflect commentary before the main results presentation anticipated at ESMO 2026.

## Open Medical Affairs question

What efficacy, survival-maturity and tolerability details are needed before the announcement can support a complete benefit–risk discussion?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Favorable topline reactions do not yet constitute a full benefit–risk assessment
- F2. The perceived advance is anchored in limitations of current options and the value of direct comparison
- F3. Heterogeneity sustains interest in combinations beyond the single-agent comparison
- F4. Potential practice impact remains an explicit question pending fuller data

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 14 | 12 | 12 | 11 | none recorded | 3 |
| F2 | 8 | 4 | 3 | 3 | none recorded | 3 |
| F3 | 1 | 1 | 1 | 1 | none recorded | 2 |
| F4 | 3 | 3 | 2 | 3 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 2 | 0 | 0 | 10 | 16 | 0 | 12 posts and articles | yes |
| F2 | 1 | 1 | 0 | 2 | 4 | 13 | 1 | 2 posts and articles, 1 podcast or video | yes |
| F3 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 post or article | yes |
| F4 | 1 | 1 | 0 | 0 | 1 | 4 | 1 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS): F1 (5 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (5 shared claims)
- Population and setting: F1 (2 shared claims), F2 (4 shared claims)
- The comparison: F1 (6 shared claims), F2 (5 shared claims), F3 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. The perceived advance is anchored in limitations of current options and the value of direct comparison

In a YouTube video, a speaker described the question of whether divarasib could improve outcomes relative to sotorasib or adagrasib for recurrent, advanced NSCLC with a KRAS G12C mutation.

This discussion concerns the study's design and comparative purpose, not KRAScendo-1 results.

The speaker refers first to Phase I and then to Phase II supporting evidence without clarifying the change.

Source: YouTube video.

### F4. Potential practice impact remains an explicit question pending fuller data

An X post listing KRAScendo-1 among several studies asked which results might change clinical practice.

The question concerned multiple studies, not KRAScendo-1 alone.

The author's clinical role is not stated in the sources reviewed for this edition.

The exchange was not evaluated in full, so additional views may be missing.

Source: X thread, 2026-10-11.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified HCP statements with short source quotes and links | 27 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 17 | Counts free |
| Speaker attribution for cited voices | 15 | Paid |

## Trial aspects

8 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) | discussed | 6 | 7 |
| Secondary endpoints | discussed | 5 | 6 |
| Population and setting | discussed | 7 | 3 |
| The comparison | discussed | 12 | 10 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 3 | 1 |
| Perceived advance and possible practice impact | discussed | 9 | 9 |
| Topline uncertainty and presentation expectations | discussed | 11 | 8 |
| Heterogeneity and possible combination strategies | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 25 | 15 |
| YouTube | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-06-26 to 2026-10-11
- Cited window: 2026-06-18 to 2026-10-11
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified HCP statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Registry: NCT06497556 (https://clinicaltrials.gov/study/NCT06497556)
- Study IDs: BO45217 · 2024-510908-37-00 (EU CT Number)
- Sponsor: Hoffmann-La Roche
- Collaborators: Chugai Pharmaceutical
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 338 (actual)
- Start: 2024-09-23 (actual)
- Primary completion: 2026-05-19 (actual)
- Primary endpoint: Progression-Free Survival (PFS) (Up to approximately 4 years)
- Intervention: Divarasib (drug)
- Intervention: Sotorasib (drug)
- Intervention: Adagrasib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Most efficacy reactions describe company-announced topline findings rather than independent assessment of a full trial dataset; numerical treatment effects and substantive comparative safety commentary are unavailable here.
- No full protocol, exact-trial results publication or divarasib prescribing label was available among the sources reviewed. This does not establish that such materials do not exist.
- Discussion using unnamed references or different transcription forms may be missing, so the report is not an exhaustive account of public or clinical opinion.
- One included social-media discussion was not fully evaluated beyond the statements described in this report; additional views from it may be missing.
- Repeated posts and shared company headlines do not represent independent clinical assessments.
- The video account has no available publication date, preventing reliable chronological comparison with the dated posts.
- Chandrakanth's clinical role is not established in the sources reviewed for this edition.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-18: current edition

Last checked for new commentary 2026-10-18. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (27 verified HCP statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (13 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/krascendo-1-nct06497556
- Agents: POST https://www.erudio.com/api/orders with {"report": "krascendo-1-nct06497556", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=krascendo-1-06497556

## Cite

Erudio Health. Krascendo 1 (NCT06497556): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/krascendo-1-nct06497556

## Machine access

- JSON: https://www.erudio.com/reports/krascendo-1-nct06497556.json
- Markdown: https://www.erudio.com/reports/krascendo-1-nct06497556.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "krascendo-1-06497556"}`